217 related articles for article (PubMed ID: 35790783)
1. Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine.
Lin YJ; Lin MY; Chuang YS; Liu LT; Kuo TY; Chen C; Ganesan S; Fattom A; Bitko V; Lien CE
Sci Rep; 2022 Jul; 12(1):11369. PubMed ID: 35790783
[TBL] [Abstract][Full Text] [Related]
2. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
[TBL] [Abstract][Full Text] [Related]
3. Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
Kuo TY; Lien CE; Lin YJ; Lin MY; Wu CC; Tang WH; Campbell JD; Traquina P; Chuang YS; Liu LT; Cheng J; Chen C
J Infect Dis; 2022 Nov; 226(9):1562-1567. PubMed ID: 35451470
[TBL] [Abstract][Full Text] [Related]
4. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
Lien CE; Lin YJ; Chen C; Lian WC; Kuo TY; Campbell JD; Traquina P; Lin MY; Liu LT; Chuang YS; Ko HY; Liao CC; Chen YH; Jan JT; Ma HH; Sun CP; Lin YS; Wu PY; Wang YC; Tao MH; Lin YL
Sci Rep; 2021 Apr; 11(1):8761. PubMed ID: 33888840
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
Torales J; Cuenca-Torres O; Barrios L; Armoa-Garcia L; Estigarribia G; Sanabria G; Lin MY; Antonio Estrada J; Estephan L; Cheng HY; Chen C; Janssen R; Lien CE
Vaccine; 2023 Jan; 41(1):109-118. PubMed ID: 36404171
[TBL] [Abstract][Full Text] [Related]
7. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
Hsieh SM; Chang SC; Cheng HY; Shih SR; Lien CE
Infect Dis Ther; 2022 Aug; 11(4):1493-1504. PubMed ID: 35579840
[TBL] [Abstract][Full Text] [Related]
8. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
9. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
[TBL] [Abstract][Full Text] [Related]
11. Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.
Sui Y; Andersen H; Li J; Hoang T; Bekele Y; Kar S; Lewis MG; Berzofsky JA
Front Immunol; 2023; 14():1154496. PubMed ID: 37020550
[TBL] [Abstract][Full Text] [Related]
12. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
Liu X; Luongo C; Matsuoka Y; Park HS; Santos C; Yang L; Moore IN; Afroz S; Johnson RF; Lafont BAP; Martens C; Best SM; Munster VJ; Hollý J; Yewdell JW; Le Nouën C; Munir S; Buchholz UJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876520
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study.
Lien CE; Liu MC; Wang NC; Liu LT; Wu CC; Tang WH; Lian WC; Huang KA; Chen C
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140202
[TBL] [Abstract][Full Text] [Related]
14. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
Estephan L; Lin YC; Lin YT; Chen YH; Pan SC; Hsieh SM; Torkehagen PF; Weng YJ; Cheng HY; Estrada JA; Waits A; Chen C; Lien CE
Vaccine; 2023 May; 41(23):3497-3505. PubMed ID: 37080829
[TBL] [Abstract][Full Text] [Related]
16. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Estephan L; Liu LT; Lien CE; Smith ER; Gurwith M; Chen RT;
Vaccine; 2023 Apr; 41(15):2615-2629. PubMed ID: 36925422
[TBL] [Abstract][Full Text] [Related]
17. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.
Liu X; Park HS; Matsuoka Y; Santos C; Yang L; Luongo C; Moore IN; Johnson RF; Garza NL; Zhang P; Lusso P; Best SM; Buchholz UJ; Le Nouën C
bioRxiv; 2022 Dec; ():. PubMed ID: 36561185
[TBL] [Abstract][Full Text] [Related]
18. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
Hill-Batorski L; Bowen R; Bielefeldt-Ohmann H; Moser MJ; Matejka SM; Marshall D; Kawaoka Y; Neumann G; Bilsel P
Vaccine; 2024 Apr; 42(11):2770-2780. PubMed ID: 38508930
[TBL] [Abstract][Full Text] [Related]
19. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.
Tabynov K; Solomadin M; Turebekov N; Babayeva M; Fomin G; Yadagiri G; Renu S; Yerubayev T; Petrovsky N; Renukaradhya GJ; Tabynov K
Sci Rep; 2023 Jul; 13(1):12115. PubMed ID: 37495639
[TBL] [Abstract][Full Text] [Related]
20. Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters.
Stark FC; Akache B; Deschatelets L; Tran A; Stuible M; Durocher Y; McCluskie MJ; Agbayani G; Dudani R; Harrison BA; Renner TM; Makinen SR; Bavananthasivam J; Duque D; Gagne M; Zimmermann J; Zarley CD; Cochrane TR; Handfield M
Sci Rep; 2022 Jun; 12(1):9772. PubMed ID: 35697917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]